LSL Pharma Group Inc.
LSL.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.22M | 4.82M | 3.85M | 2.94M | 3.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.22M | 4.82M | 3.85M | 2.94M | 3.06M |
| Cost of Revenue | 3.73M | 3.37M | 2.80M | 2.06M | 1.94M |
| Gross Profit | 1.49M | 1.45M | 1.05M | 875.40K | 1.12M |
| SG&A Expenses | 1.27M | 1.20M | 970.10K | 786.70K | 1.23M |
| Depreciation & Amortization | -- | -- | -72.90K | 25.70K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.00M | 4.57M | 3.69M | 2.88M | 3.17M |
| Operating Income | 219.70K | 256.80K | 154.30K | 63.10K | -103.80K |
| Income Before Tax | -281.20K | -189.50K | 3.25M | -283.00K | -377.10K |
| Income Tax Expenses | -- | -- | 35.70K | -- | -- |
| Earnings from Continuing Operations | -281.20K | -189.50K | 3.21M | -283.00K | -377.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -281.20K | -189.50K | 3.21M | -283.00K | -377.10K |
| EBIT | 219.70K | 256.80K | 154.30K | 63.10K | -103.80K |
| EBITDA | 730.70K | 667.20K | 343.60K | 322.60K | 149.10K |
| EPS Basic | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 115.53M | 115.53M | 115.93M | 115.08M | 105.77M |
| Average Diluted Shares Outstanding | 115.53M | 115.53M | 115.93M | 115.28M | 105.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |